Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Status:
Completed
Trial end date:
2014-11-28
Target enrollment:
Participant gender:
Summary
To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of
Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or
local ablation).